Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Horizon Therapeutics PublicCatalentUCBMERCK Kommanditgesellschaft auf AktienGenmab A/S
SymbolNASDAQ:HZNPNYSE:CTLTOTCMKTS:UCBJFOTCMKTS:MKGAFOTCMKTS:GNMSF
Price Information
Current Price$93.27$110.60$98.00$177.75$354.02
52 Week RangeBuyBuyBuyN/ABuy
MarketRank™
Overall Score2.41.71.00.50.6
Analysis Score3.52.40.00.00.0
Community Score3.32.42.32.31.9
Dividend Score0.00.00.00.00.0
Ownership Score1.71.70.00.00.0
Earnings & Valuation Score3.81.92.50.01.3
Analyst Ratings
Consensus RecommendationBuyBuyBuyN/ABuy
Consensus Price Target$111.36$125.13N/AN/AN/A
% Upside from Price Target19.40% upside13.13% upsideN/AN/AN/A
Trade Information
Market Cap$20.90 billion$18.83 billion$19.06 billion$22.97 billion$21.84 billion
Beta1.151.50.560.70.83
Average Volume1,952,2051,063,6414125401,495
Sales & Book Value
Annual Revenue$1.30 billion$3.09 billion$5.50 billion$18.09 billion$804.57 million
Price / Sales16.086.083.461.2727.14
Cashflow$4.20 per share$3.59 per share$5.13 per share$37.82 per share$4.62 per share
Price / Cash22.2230.8219.094.7076.64
Book Value$11.67 per share$18.71 per share$40.36 per share$155.24 per share$34.13 per share
Price / Book7.995.912.431.1510.37
Profitability
Net Income$573.02 million$173 million$887.04 million$1.48 billion$324.68 million
EPS$1.94$1.88$5.82N/AN/A
Trailing P/E Ratio25.4870.4516.840.005.03
Forward P/E Ratio21.6939.9314.24
P/E Growth0.592.68N/AN/AN/A
Net Margins43.55%9.25%N/A10.92%51.02%
Return on Equity (ROE)25.66%14.20%N/A14.29%34.38%
Return on Assets (ROA)14.19%4.83%N/A5.90%30.65%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.26%0.97%N/AN/AN/A
Current Ratio3.49%2.56%N/A1.06%8.64%
Quick Ratio3.39%2.14%N/A0.70%8.64%
Ownership Information
Institutional Ownership Percentage88.59%97.84%N/AN/A0.04%
Insider Ownership Percentage4.30%1.00%N/AN/AN/A
Miscellaneous
Employees1,39514,0007,82058,127781
Shares Outstanding224.07 million170.23 million194.51 million129.24 million61.69 million
Next Earnings Date5/5/2021 (Confirmed)5/4/2021 (Estimated)5/27/2021 (Estimated)5/13/2021 (Estimated)5/5/2021 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200-Day Moving Average of $374.80Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200-Day Moving Average of $374.80
americanbankingnews.com - April 17 at 2:14 AM
Seagens (SGEN) Tisotumab Vedotin BLA Gets FDA Priority ReviewSeagen's (SGEN) Tisotumab Vedotin BLA Gets FDA Priority Review
finance.yahoo.com - April 12 at 1:10 PM
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical CancerGenmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
finance.yahoo.com - April 9 at 5:33 PM
Genmab A/S (OTCMKTS:GNMSF) Shares Pass Above Fifty Day Moving Average of $339.28Genmab A/S (OTCMKTS:GNMSF) Shares Pass Above Fifty Day Moving Average of $339.28
americanbankingnews.com - April 9 at 3:22 AM
Genmab A/S (OTCMKTS:GNMSF) Short Interest Up 46.0% in MarchGenmab A/S (OTCMKTS:GNMSF) Short Interest Up 46.0% in March
americanbankingnews.com - April 1 at 7:24 AM
Genmab A/S (OTCMKTS:GNMSF) Stock Price Passes Below Fifty Day Moving Average of $353.29Genmab A/S (OTCMKTS:GNMSF) Stock Price Passes Below Fifty Day Moving Average of $353.29
americanbankingnews.com - March 31 at 2:20 AM
Is Genmab A/S (GMAB) Stock a Buy For 2021?Is Genmab A/S (GMAB) Stock a Buy For 2021?
finance.yahoo.com - February 19 at 3:01 PM
Genmab, Seagen File US Application For Tisotumab Vedotin In Cervical Cancer SettingGenmab, Seagen File US Application For Tisotumab Vedotin In Cervical Cancer Setting
finance.yahoo.com - February 11 at 9:13 AM
Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical CancerGenmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
finance.yahoo.com - February 10 at 7:02 PM
Top-Rated Stocks: Ligand Pharmaceuticals Sees Composite Rating Climb To 97Top-Rated Stocks: Ligand Pharmaceuticals Sees Composite Rating Climb To 97
finance.yahoo.com - January 20 at 2:25 PM
Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVieGenmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
finance.yahoo.com - January 13 at 9:46 AM
Genmab to Present at the 39th Annual J.P. Morgan Healthcare ConferenceGenmab to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 12:19 PM
Genmab (GMAB) Begins Phase III Study on Cervical Cancer DrugGenmab (GMAB) Begins Phase III Study on Cervical Cancer Drug
finance.yahoo.com - January 5 at 4:10 PM
AbbVie (ABBV) Outperforms Industry Year to Date: Heres WhyAbbVie (ABBV) Outperforms Industry Year to Date: Here's Why
finance.yahoo.com - December 28 at 1:42 PM
Genmab A-S Stock , GNMSFGenmab A-S Stock , GNMSF
markets.businessinsider.com - December 24 at 11:20 PM
Stocks Showing Improved Relative Strength: Revance TherapeuticsStocks Showing Improved Relative Strength: Revance Therapeutics
finance.yahoo.com - December 23 at 2:21 PM
Sarepta Therapeutics Sees Relative Strength Rating Improve To 74Sarepta Therapeutics Sees Relative Strength Rating Improve To 74
finance.yahoo.com - December 9 at 3:15 PM
Sarepta Therapeutics Earns Relative Strength Rating UpgradeSarepta Therapeutics Earns Relative Strength Rating Upgrade
finance.yahoo.com - December 7 at 3:47 PM
Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung CancerGenmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer
finance.yahoo.com - December 3 at 4:14 PM
Genmab Announces Enapotamab Vedotin UpdateGenmab Announces Enapotamab Vedotin Update
finance.yahoo.com - November 24 at 11:23 AM
Genmab to Present at Jefferies Virtual London Healthcare ConferenceGenmab to Present at Jefferies Virtual London Healthcare Conference
finance.yahoo.com - November 10 at 9:10 AM
Genmab A/S (GMAB) Q3 2020 Earnings Call TranscriptGenmab A/S (GMAB) Q3 2020 Earnings Call Transcript
fool.com - November 5 at 4:37 AM
Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim AnalysisGenmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis
finance.yahoo.com - October 21 at 6:10 PM
Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
finance.yahoo.com - September 21 at 1:27 PM
Genmab Announces that Janssen has Submitted a Supplemental Biologics License Application to U.S. FDA for use of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in Patients with Light-chain (AL) AmyloidosisGenmab Announces that Janssen has Submitted a Supplemental Biologics License Application to U.S. FDA for use of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in Patients with Light-chain (AL) Amyloidosis
finance.yahoo.com - September 10 at 8:34 AM
DateCompanyBrokerageAction
3/29/2021Horizon Therapeutics PublicMorgan StanleyReiterated Rating
3/25/2021Horizon Therapeutics PublicGuggenheimBoost Price Target
3/24/2021Horizon Therapeutics PublicCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated Rating
3/23/2021Horizon Therapeutics PublicStifel NicolausBoost Price Target
3/19/2021Horizon Therapeutics PublicJefferies Financial GroupReiterated Rating
3/17/2021Horizon Therapeutics PublicWolfe ResearchInitiated Coverage
2/9/2021Horizon Therapeutics PublicBank of AmericaReiterated Rating
11/3/2020Horizon Therapeutics PublicBMO Capital MarketsBoost Price Target
9/9/2020Horizon Therapeutics PublicJPMorgan Chase & Co.Initiated Coverage
7/22/2020Horizon Therapeutics PublicPiper SandlerBoost Price Target
3/2/2021CatalentArgusBoost Price Target
2/3/2021CatalentUBS GroupBoost Price Target
2/3/2021CatalentRoyal Bank of CanadaBoost Price Target
11/5/2020CatalentDeutsche Bank AktiengesellschaftBoost Price Target
11/4/2020CatalentRobert W. BairdBoost Price Target
6/15/2020UCBBarclaysReiterated Rating
10/1/2018Genmab A/SHC WainwrightReiterated Rating
(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.